Key advances in diabetes and rare diseases are apparent from recent pipeline developments at Novo Nordisk. Novo Nordisk's semaglutide, a new GLP-1 receptor agonist (new class of drugs), was found to provide 15% reduction in HbA1c test results from diabetes patients diagnosed with Type 2 versus only about mid-rangeical available treatments providing approximately]a common). This innovation is a significant advance in diabetes management, showing greater efficacy for glucose control.
Terms like "GLP-1 receptor agonist" and "HbA1c reduction", reveal both the nature of Novo Nordisk's advances. For example, semaglutide to help regulate glucose works by mimicking a natural hormone involved in the regulation of blood sugar levels.
This is clear from examples coming out of every industry event for the past 60 days. Novo Nordisk, for example has managed to cut the time needed by patients and healthcare professionals who inject insulin through its FlexTouch®, an easy-to-use injection device approved recently that simply reduces contact with over fast percentage of people. This development underlines the companys focus on enhancing convenience for patients, and compliance to patient care.
Insights from the experts highlight why these innovations are important. "Our novel pipeline is designed to offer a breakthrough in diabetes treatment, with better and more convenient solutions leading to improvements for patients" said Dr Lars Jørgensen...Senior researcher at Novo Nordisk.
As evidence-based responses reveal, Novo Nordisk is also developing therapies for rare diseases. One case example is their new drug, congenital hyperinsulinemia treatment has been shown to improve metabolic control by 40% in clinical trials and could have an incredible impact on patients diagnosed with such rare metabolic diseases.
novo nordisk pipeline continues to deliver innovative treatments for prolonged insulin care and rare diseases with their latest drugs in the pipeline.